Literature DB >> 24114627

Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Alexis D Leal1, Carrie A Thompson, Alice H Wang, Robert A Vierkant, Thomas M Habermann, Julie A Ross, Ruben A Mesa, Beth A Virnig, James R Cerhan.   

Abstract

Classical myeloproliferative neoplasms (MPNs) are composed of essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), the etiology of which is largely unknown. We investigated the role of anthropometric, medical and lifestyle factors with risk of MPN in a prospective cohort of 27,370 women aged 55-69 years at enrollment. After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV, 21 MF). Risk factor profiles were mostly unique for the two most common types, ET and PV. ET was associated with energy balance factors including body mass index (RR = 1.52 for >29.3 vs. <23.4 kg/m(2) ; p-trend = 0.042), physical activity (RR = 0.66 for high vs. low; p-trend = 0.04) and adult onset diabetes (RR = 1.82; p = 0.009), while PV was not. PV was associated with current smoking (RR = 2.83; p-trend = 0.016), while ET was not. Regular use of aspirin was associated with lower risk of ET (RR = 0.68; p = 0.017). These results broadly held in multivariate models. Our results suggest distinct etiologies for these MPN subtypes and raise mechanistic hypotheses related to obesity-related inflammatory pathways for ET and smoking-related carcinogenic pathways for PV. Regular aspirin use may lower risk for ET.
© 2013 UICC.

Entities:  

Keywords:  essential thrombocythemia; lifestyle; myeloproliferative neoplasm; polycythemia vera; risk factor

Mesh:

Year:  2013        PMID: 24114627      PMCID: PMC3947165          DOI: 10.1002/ijc.28492

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  39 in total

1.  Familial polycythemia vera: results from the Swedish Family-Cancer Database.

Authors:  K Hemminki; Y Jiang
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

Review 2.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

Authors:  A J Dannenberg; N K Altorki; J O Boyle; C Dang; L R Howe; B B Weksler; K Subbaramaiah
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

3.  Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study.

Authors:  A R Folsom; L H Kushi; K E Anderson; P J Mink; J E Olson; C P Hong; T A Sellers; D Lazovich; R J Prineas
Journal:  Arch Intern Med       Date:  2000-07-24

4.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 5.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

Authors:  Michael J Thun; S Jane Henley; Carlo Patrono
Journal:  J Natl Cancer Inst       Date:  2002-02-20       Impact factor: 13.506

6.  Occupational risk for hematological malignancies.

Authors:  P Pasqualetti; R Casale; D Colantonio; A Collacciani
Journal:  Am J Hematol       Date:  1991-10       Impact factor: 10.047

7.  Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects.

Authors:  G G Giles; J N Lickiss; M J Baikie; R M Lowenthal; J Panton
Journal:  J Natl Cancer Inst       Date:  1984-06       Impact factor: 13.506

8.  Non-steroidal anti-inflammatory drug use and risk of adult leukemia.

Authors:  Christine M Kasum; Cindy K Blair; Aaron R Folsom; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-06       Impact factor: 4.254

9.  Patterns of mortality among commercial pressmen.

Authors:  S R Zoloth; D M Michaels; J R Villalbi; M Lacher
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

10.  Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study.

Authors:  F Murphy; M E Kroll; K Pirie; G Reeves; J Green; V Beral
Journal:  Br J Cancer       Date:  2013-05-02       Impact factor: 7.640

View more
  18 in total

Review 1.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 2.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 3.  Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.

Authors:  Dimitrios Tsilingiris; Narjes Nasiri-Ansari; Nikolaos Spyrou; Faidon Magkos; Maria Dalamaga
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

4.  Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.

Authors:  Samer A Srour; Susan S Devesa; Lindsay M Morton; David P Check; Rochelle E Curtis; Martha S Linet; Graça M Dores
Journal:  Br J Haematol       Date:  2016-04-07       Impact factor: 6.998

5.  Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.

Authors:  Alexis D Leal; Carrie A Thompson; Alice H Wang; Robert A Vierkant; Thomas M Habermann; Julie A Ross; Ruben A Mesa; Beth A Virnig; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-12       Impact factor: 4.254

Review 6.  The Microenvironment in Myeloproliferative Neoplasms.

Authors:  Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Hematol Oncol Clin North Am       Date:  2020-12-09       Impact factor: 3.722

7.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

Review 8.  Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

Authors:  Moo-Kon Song; Byeong-Bae Park; Ji-Eun Uhm
Journal:  Int J Mol Sci       Date:  2018-03-18       Impact factor: 5.923

9.  Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben Mesa; Xiaomei Ma
Journal:  Int J Cancer       Date:  2020-01-29       Impact factor: 7.396

10.  Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben A Mesa; Xiaomei Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-31       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.